Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA LEVELS AFTER BISPHOSPHONATES TREATMENT IN-VITRO AND IN PATIENTS WITH MALIGNANCY
Autore:
SAUTY A; PECHERSTORFER M; ZIMMERROTH I; FIORONI P; JUILLERAT L; MARKERT M; LUDWIG H; LEUENBERGER P; BURCKHARDT P; THIEBAUD D;
Indirizzi:
CHU VAUDOIS,DEPT INTERNAL MED,BH10 CH-1011 LAUSANNE SWITZERLAND CHU VAUDOIS,DEPT INTERNAL MED CH-1011 LAUSANNE SWITZERLAND WILHELMINENSPITAL STADT WIEN,DEPT MED & MED ONCOL 1 VIENNA AUSTRIA UNIV HOSP,CLIN CHEM LAB LAUSANNE SWITZERLAND
Titolo Testata:
Bone
fascicolo: 2, volume: 18, anno: 1996,
pagine: 133 - 139
SICI:
8756-3282(1996)18:2<133:IATLAB>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE-PHASE RESPONSE; PAGETS-DISEASE; MONONUCLEAR PHAGOCYTES; GENE-EXPRESSION; BONE-DISEASE; APD; PAMIDRONATE; CACHECTIN; PATHOGENESIS; OSTEOPOROSIS;
Keywords:
ACUTE PHASE REACTION; BISPHOSPHONATES; INTERLEUKIN-1; INTERLEUKIN-6; TNF-ALPHA; C-REACTIVE PROTEIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
A. Sauty et al., "INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA LEVELS AFTER BISPHOSPHONATES TREATMENT IN-VITRO AND IN PATIENTS WITH MALIGNANCY", Bone, 18(2), 1996, pp. 133-139

Abstract

Bisphosphonates are potent inhibitors of bone resorption and are widely used in the treatment of bone diseases, One of the side effects of administered aminobisphosphonates is transient fever and some biological changes that are suggestive of an acute phase response, Pamidronate[(3-amino-1-hydroxypropylidene)-1, I-bisphosphonate] and ibandronate [1-hydroxy-3-(methylpentylamino) propylidenebisphosphonate] incubated in heparinized whole blood at doses of 10(-4) and 10(-5) mol/L, induced the production of tumor necrosis factor alpha (TNF alpha). Moreover,pamidronate was found to slightly stimulate interleukin-6 IL-6 production, In contrast, clodronate (dichloromethylenebisphosphonate) did not increase IL-6 or TNF alpha, To investigate these phenomena in vivo, acute phase reaction was assessed in patients with malignant disease treated with 60 mg of pamidronate (n = 29), 1500 mg of clodronate (n = 8), or 0.5-2 mg of ibandronate (n = 6), all given intravenously, A significant decrease in lymphocyte and leukocyte count was observed in the pamidronate group, In the same group, seven patients (24%) showed a transient increase of body temperature above 37 degrees C,vith an increase greater than or equal to 0.5 degrees C at 24 h, These changes were not found in the patients treated with clodronate or ibandronate, Plasma IL-6 and TNF alpha levels increased significantly after pamidronate treatment, whereas no change was seen after clodronate infusion, The peak of IL-6 level (53.7 +/- 14.1 [SEM] pg/mL) was observed at 24 h,and that of TNF alpha level (26.9 +/- 3.4 pg/mL) at 48 h after the beginning of pamidronate administration (values before treatment, respectively: 28.6 +/- 7.1 pg/mL, p < 0.006; and 13.1 +/- 1.5 pg/mL, p = 0.0001), The peak of C-reactive protein (CRP) level was found at 48 h (41.0 +/- 7.8 vs, 25.5 +/- 5.6 mg/L before treatment, p < 0.01) and CRP levels were strongly correlated with IL-6 levels (rho = 0.65, p < 0.001), Only one patient treated with ibandronate showed an increase in IL-6 and CRP levels, Patients treated with pamidronate, whose body temperatures were increased at 24 h, had a greater increases of circulating IL-6, TNF alpha, and CRP at 24 h and 48 h than patients without temperature increase, These results suggest that pamidronate treatment, but not clodronate and possibly not ibandronate at the doses used, inducedan increase in the plasma levels of IL-6 and TNF alpha, which may be responsible for the acute phase reaction observed clinically.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 23:07:40